Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peptide Fragments | 44 | 2017 | 422 | 5.110 |
Why?
|
| Angiotensin I | 40 | 2017 | 262 | 4.600 |
Why?
|
| Angiotensin II | 35 | 2015 | 279 | 3.200 |
Why?
|
| Muscle, Smooth, Vascular | 11 | 2008 | 71 | 1.380 |
Why?
|
| Receptors, Angiotensin | 15 | 2003 | 77 | 1.150 |
Why?
|
| Peptidyl-Dipeptidase A | 10 | 2017 | 142 | 1.020 |
Why?
|
| Antihypertensive Agents | 7 | 2015 | 339 | 1.010 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 546 | 0.890 |
Why?
|
| Cell Proliferation | 4 | 2014 | 573 | 0.830 |
Why?
|
| Animals | 46 | 2016 | 7297 | 0.830 |
Why?
|
| Rats | 26 | 2015 | 1604 | 0.800 |
Why?
|
| Neovascularization, Pathologic | 2 | 2012 | 81 | 0.750 |
Why?
|
| Fibroblasts | 2 | 2012 | 103 | 0.720 |
Why?
|
| Astrocytes | 5 | 2005 | 49 | 0.680 |
Why?
|
| MAP Kinase Signaling System | 5 | 2015 | 57 | 0.670 |
Why?
|
| Lung Neoplasms | 4 | 2011 | 384 | 0.670 |
Why?
|
| Cells, Cultured | 16 | 2012 | 799 | 0.660 |
Why?
|
| Hypertension | 8 | 2015 | 906 | 0.620 |
Why?
|
| Cell Division | 6 | 2005 | 97 | 0.600 |
Why?
|
| Myocytes, Cardiac | 2 | 2008 | 87 | 0.580 |
Why?
|
| Dual Specificity Phosphatase 1 | 5 | 2015 | 29 | 0.570 |
Why?
|
| Renin-Angiotensin System | 7 | 2012 | 182 | 0.560 |
Why?
|
| Rats, Sprague-Dawley | 15 | 2012 | 747 | 0.540 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2009 | 90 | 0.520 |
Why?
|
| Blood Pressure | 7 | 2015 | 804 | 0.520 |
Why?
|
| Adenocarcinoma | 3 | 2012 | 301 | 0.500 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2012 | 113 | 0.490 |
Why?
|
| Peptide Hormones | 1 | 2014 | 11 | 0.480 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 494 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2012 | 103 | 0.470 |
Why?
|
| Angiotensins | 3 | 2011 | 49 | 0.440 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 7 | 0.440 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 6 | 2015 | 44 | 0.430 |
Why?
|
| Carboxypeptidases | 3 | 2005 | 20 | 0.400 |
Why?
|
| RNA, Messenger | 12 | 2009 | 514 | 0.400 |
Why?
|
| Imidazoles | 11 | 2008 | 104 | 0.390 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2008 | 37 | 0.390 |
Why?
|
| Autonomic Nervous System | 1 | 2011 | 42 | 0.390 |
Why?
|
| Losartan | 13 | 2008 | 68 | 0.390 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 441 | 0.380 |
Why?
|
| Ventricular Remodeling | 4 | 2011 | 52 | 0.370 |
Why?
|
| Brain | 3 | 2011 | 930 | 0.350 |
Why?
|
| Gene Expression Regulation | 4 | 2012 | 481 | 0.340 |
Why?
|
| Signal Transduction | 7 | 2012 | 666 | 0.340 |
Why?
|
| Fibrosis | 5 | 2016 | 102 | 0.340 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2008 | 4 | 0.340 |
Why?
|
| Receptors, G-Protein-Coupled | 5 | 2009 | 89 | 0.330 |
Why?
|
| Medulla Oblongata | 5 | 2012 | 53 | 0.330 |
Why?
|
| Tetrazoles | 10 | 2006 | 71 | 0.320 |
Why?
|
| Animals, Newborn | 5 | 2012 | 111 | 0.320 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2008 | 74 | 0.320 |
Why?
|
| Heart Ventricles | 1 | 2008 | 107 | 0.320 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 6 | 2008 | 68 | 0.310 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 4 | 2012 | 37 | 0.300 |
Why?
|
| Phosphorylation | 4 | 2015 | 225 | 0.270 |
Why?
|
| Phospholipase D | 2 | 1995 | 5 | 0.270 |
Why?
|
| Cell Line, Tumor | 5 | 2012 | 680 | 0.260 |
Why?
|
| Mice, Nude | 5 | 2012 | 276 | 0.250 |
Why?
|
| Vasoconstrictor Agents | 3 | 2015 | 62 | 0.240 |
Why?
|
| Renin | 6 | 2012 | 112 | 0.240 |
Why?
|
| Mice | 7 | 2016 | 2368 | 0.210 |
Why?
|
| Cardiomegaly | 1 | 2011 | 30 | 0.210 |
Why?
|
| Humans | 20 | 2017 | 29093 | 0.200 |
Why?
|
| Myocardium | 3 | 2012 | 170 | 0.200 |
Why?
|
| Male | 18 | 2016 | 17807 | 0.200 |
Why?
|
| Endothelin-1 | 2 | 2012 | 17 | 0.190 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 50 | 0.180 |
Why?
|
| Rats, Inbred Lew | 4 | 2015 | 116 | 0.180 |
Why?
|
| Carotid Artery Injuries | 1 | 1999 | 9 | 0.170 |
Why?
|
| Tunica Intima | 1 | 1999 | 59 | 0.170 |
Why?
|
| Baroreflex | 2 | 2011 | 84 | 0.170 |
Why?
|
| Carotid Artery, Common | 1 | 1999 | 37 | 0.170 |
Why?
|
| Flavonoids | 2 | 2008 | 18 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2008 | 77 | 0.160 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2012 | 32 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2012 | 223 | 0.160 |
Why?
|
| Endothelium, Vascular | 3 | 1999 | 145 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2008 | 134 | 0.160 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2017 | 5 | 0.160 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 40 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 2 | 2015 | 66 | 0.150 |
Why?
|
| Binding, Competitive | 4 | 2001 | 38 | 0.150 |
Why?
|
| Hypertension, Renal | 2 | 2006 | 29 | 0.140 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 4 | 0.140 |
Why?
|
| Spasm | 1 | 2016 | 5 | 0.140 |
Why?
|
| Prostaglandins | 4 | 2003 | 17 | 0.140 |
Why?
|
| Pyridines | 4 | 2005 | 78 | 0.130 |
Why?
|
| Neoplasms | 2 | 2014 | 610 | 0.130 |
Why?
|
| Smad2 Protein | 1 | 2015 | 7 | 0.130 |
Why?
|
| Arterioles | 1 | 2015 | 12 | 0.130 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2015 | 7 | 0.130 |
Why?
|
| Smad3 Protein | 1 | 2015 | 11 | 0.130 |
Why?
|
| Pancreas | 1 | 1995 | 79 | 0.120 |
Why?
|
| Receptor, Angiotensin, Type 1 | 6 | 2004 | 75 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 7 | 2010 | 158 | 0.120 |
Why?
|
| Epoprostenol | 4 | 1997 | 9 | 0.120 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 280 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2015 | 369 | 0.110 |
Why?
|
| Calcium | 6 | 1995 | 296 | 0.110 |
Why?
|
| Kinetics | 3 | 2006 | 205 | 0.110 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 10 | 0.110 |
Why?
|
| Osteoclasts | 1 | 2012 | 22 | 0.110 |
Why?
|
| Cerebellum | 2 | 2005 | 29 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2010 | 281 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 298 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2012 | 97 | 0.100 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 9 | 0.100 |
Why?
|
| Collagen | 1 | 2012 | 217 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2001 | 143 | 0.100 |
Why?
|
| DNA | 1 | 2012 | 204 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 28 | 0.090 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2012 | 30 | 0.090 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2009 | 29 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 34 | 0.090 |
Why?
|
| Chorioallantoic Membrane | 1 | 2009 | 4 | 0.090 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 33 | 0.090 |
Why?
|
| Type C Phospholipases | 2 | 2001 | 9 | 0.090 |
Why?
|
| Chick Embryo | 1 | 2009 | 73 | 0.090 |
Why?
|
| Valine | 2 | 2006 | 17 | 0.090 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 114 | 0.090 |
Why?
|
| Butadienes | 1 | 2008 | 7 | 0.080 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2008 | 10 | 0.080 |
Why?
|
| Vanadates | 1 | 2008 | 2 | 0.080 |
Why?
|
| Okadaic Acid | 1 | 2008 | 3 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 136 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 248 | 0.080 |
Why?
|
| Nitriles | 1 | 2008 | 22 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 106 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2016 | 454 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 83 | 0.080 |
Why?
|
| Leucine | 1 | 2008 | 24 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2009 | 179 | 0.080 |
Why?
|
| Solitary Nucleus | 1 | 2008 | 34 | 0.080 |
Why?
|
| Heart Rate | 2 | 2008 | 315 | 0.080 |
Why?
|
| Biphenyl Compounds | 3 | 1997 | 19 | 0.080 |
Why?
|
| Neurons | 1 | 1991 | 394 | 0.080 |
Why?
|
| Cattle | 2 | 1997 | 100 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2016 | 980 | 0.070 |
Why?
|
| Oligopeptides | 4 | 1994 | 51 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2006 | 92 | 0.070 |
Why?
|
| Enzyme Activation | 2 | 1995 | 126 | 0.070 |
Why?
|
| Aorta, Thoracic | 2 | 1996 | 72 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2009 | 641 | 0.060 |
Why?
|
| Rats, Inbred SHR | 3 | 2009 | 42 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 35 | 0.060 |
Why?
|
| Culture Media | 1 | 2004 | 39 | 0.060 |
Why?
|
| DNA Replication | 1 | 2004 | 23 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2004 | 70 | 0.060 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2004 | 3 | 0.060 |
Why?
|
| Aging | 1 | 2011 | 881 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 666 | 0.060 |
Why?
|
| Dinoprostone | 3 | 1993 | 37 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2003 | 40 | 0.060 |
Why?
|
| Cytosol | 2 | 1995 | 25 | 0.060 |
Why?
|
| Pregnancy | 1 | 2005 | 815 | 0.050 |
Why?
|
| Animals, Genetically Modified | 4 | 2006 | 67 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2011 | 80 | 0.050 |
Why?
|
| Angiotensinogen | 2 | 2012 | 73 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2011 | 183 | 0.050 |
Why?
|
| Kidney | 2 | 2003 | 485 | 0.050 |
Why?
|
| Vasodilator Agents | 2 | 1998 | 54 | 0.050 |
Why?
|
| Bradykinin | 2 | 1998 | 18 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2001 | 274 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 412 | 0.050 |
Why?
|
| Models, Biological | 2 | 2009 | 373 | 0.050 |
Why?
|
| Peptides | 2 | 2009 | 118 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 85 | 0.040 |
Why?
|
| Rats, Inbred WKY | 2 | 1995 | 24 | 0.040 |
Why?
|
| Catheterization | 1 | 1999 | 58 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1998 | 30 | 0.040 |
Why?
|
| Monocytes | 1 | 1999 | 119 | 0.040 |
Why?
|
| Female | 5 | 2010 | 18164 | 0.040 |
Why?
|
| Protein Stability | 1 | 2017 | 26 | 0.040 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1997 | 1 | 0.040 |
Why?
|
| Neprilysin | 2 | 2008 | 32 | 0.040 |
Why?
|
| Hypothalamus | 1 | 1997 | 18 | 0.040 |
Why?
|
| Thymidine | 1 | 1996 | 7 | 0.040 |
Why?
|
| Cell Count | 1 | 1996 | 50 | 0.040 |
Why?
|
| Muscle Neoplasms | 1 | 2016 | 8 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 43 | 0.030 |
Why?
|
| Lisinopril | 2 | 2006 | 28 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 1996 | 103 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 1997 | 141 | 0.030 |
Why?
|
| Hindlimb | 1 | 2016 | 57 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2016 | 89 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 224 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 213 | 0.030 |
Why?
|
| Diglycerides | 1 | 1994 | 5 | 0.030 |
Why?
|
| 1-Sarcosine-8-Isoleucine Angiotensin II | 2 | 1991 | 4 | 0.030 |
Why?
|
| Hybrid Cells | 2 | 1991 | 7 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 532 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 519 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 13 | 0.030 |
Why?
|
| Ion Channels | 1 | 2012 | 24 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2012 | 52 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2012 | 71 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 2004 | 23 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 1999 | 1013 | 0.030 |
Why?
|
| Biotransformation | 1 | 1991 | 5 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2012 | 67 | 0.030 |
Why?
|
| Angiotensin III | 1 | 1991 | 2 | 0.030 |
Why?
|
| Prostaglandins F | 1 | 1991 | 3 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 158 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1991 | 7 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1991 | 30 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 199 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 104 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 174 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 46 | 0.020 |
Why?
|
| Fibronectins | 1 | 2010 | 34 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 82 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 1990 | 19 | 0.020 |
Why?
|
| Cell Line | 1 | 1991 | 449 | 0.020 |
Why?
|
| Glioma | 1 | 1991 | 133 | 0.020 |
Why?
|
| Membranes | 1 | 2008 | 11 | 0.020 |
Why?
|
| Phenylephrine | 1 | 2008 | 27 | 0.020 |
Why?
|
| Aged | 2 | 2012 | 9487 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 9 | 0.020 |
Why?
|
| Middle Aged | 2 | 2012 | 10829 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2006 | 9 | 0.020 |
Why?
|
| Animals, Congenic | 1 | 2006 | 14 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2006 | 23 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2006 | 33 | 0.020 |
Why?
|
| Podocytes | 1 | 2006 | 20 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 30 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 1687 | 0.020 |
Why?
|
| Albuminuria | 1 | 2006 | 176 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2004 | 5 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 31 | 0.020 |
Why?
|
| Ligation | 1 | 2004 | 55 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2004 | 389 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2004 | 147 | 0.010 |
Why?
|
| Protein Binding | 1 | 2003 | 199 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 3717 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 2001 | 2 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 25 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2001 | 23 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 58 | 0.010 |
Why?
|
| Time Factors | 1 | 2006 | 2001 | 0.010 |
Why?
|
| Nitroblue Tetrazolium | 1 | 1999 | 1 | 0.010 |
Why?
|
| Hydralazine | 1 | 1999 | 8 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 23 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1999 | 26 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1999 | 103 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 117 | 0.010 |
Why?
|
| Adult | 1 | 2009 | 8420 | 0.010 |
Why?
|
| Immune Sera | 1 | 1995 | 9 | 0.010 |
Why?
|
| Aorta | 1 | 1993 | 103 | 0.010 |
Why?
|
| Swine | 1 | 1993 | 201 | 0.010 |
Why?
|
| 4-Chloromercuribenzenesulfonate | 1 | 1990 | 1 | 0.010 |
Why?
|
| Enalaprilat | 1 | 1990 | 1 | 0.010 |
Why?
|
| Dipeptides | 1 | 1990 | 9 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1990 | 26 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1990 | 93 | 0.010 |
Why?
|